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Background. The primary objective of the study was to evaluate the association between the minimum apparent 
diffusion coefficient (ADCmin) and Ki-67, an index for cellular proliferation, in non-small cell lung cancers. Also, we 
aimed to assess whether ADCmin values differ between tumour subtypes and tissue sampling method.
Methods. The patients who had diffusion weighted magnetic resonance imaging (DW-MRI) were enrolled retrospec-
tively. The correlation between ADCmin and the Ki-67 index was evaluated. 
Results. Ninety three patients, with a mean age 65 ± 11 years, with histopathologically proven adenocarcinoma 
and squamous cell carcinoma of the lungs and had technically successful DW-MRI were included in the study. The 
numbers of tumour subtypes were 47 for adenocarcinoma and 46 for squamous cell carcinoma. There was a good 
negative correlation between ADCmin values and the Ki-67 proliferation index (r = -0.837, p < 0.001). The mean ADCmin 
value was higher and the mean Ki-67 index was lower in adenocarcinomas compared to squamous cell carcinoma 
(p < 0.0001). There was no statistical difference between tissue sampling methods.
Conclusions. Because ADCmin shows a good but negative correlation with Ki-67 index, it provides an opportunity to 
evaluate tumours and their aggressiveness and may be helpful in the differentiation of subtypes non-invasively. 
Key words: diffusion weighted-magnetic resonance imaging; apparent diffusion coefficient; Ki-67 index; adenocar-
cinoma; squamous cell carcinoma
Introduction
Diffusion weighted magnetic resonance imaging 
(DW-MRI) is a promising MRI technique used in 
the evaluation of lung tumours. It has been in-
creasingly used for the detection, differential di-
agnosis and evaluation of tumour characteristics, 
including grading and prediction of the therapeu-
tic response.1-7 DW-MRI is a functional imaging 
technique that reveals physiological information 
by quantifying the diffusion of water molecules 
in tissues. The extent of this diffusion is measured 
using the apparent diffusion coefficient (ADC). 
Malignant tissues tend to have a lower ADC and 
demonstrate higher signal intensity on a DW-MRI 
image due to their increased cellularity and larger 
nuclei with abundant macromolecular proteins.8,9 
The Ki-67 protein (also known as MKI67) is a 
cellular proliferation marker. During interphase, 
the Ki-67 antigen can only be detected within the 
cell nucleus; however, in mitosis, most of the Ki-67 
is relocated to the surface of the chromosomes. Ki-
67 protein is present during all active phases of the 
cell cycle (G1, S, G2, and mitosis), but is absent in 
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resting cells (G0). The Ki-67 proliferation index, one 
of the biological markers used in histopathological 
evaluation, is an important criterion in the differ-
entiation of benign and malignant tumours.10-12 It 
is also correlated with the clinical course of cancer 
and has been shown to have prognostic value for 
treatment response, tumour recurrence and surviv-
al in brain, breast, bladder and prostate tumours, 
meningioma and nephroblastoma.13-19 The Ki-67 
index has also been used routinely in the evalua-
tion of lung tumours and has been shown to be an 
important prognostic factor for lung cancer.3,6,20-27 
Although a few studies have evaluated the associa-
tion of ADC with Ki-67 index in lung tumours3,6, 
no study has previously investigated differences 
in the ADC/Ki 67 correlation in different tumour 
subtypes. 
In this study, our primary objective was to 
evaluate whether there is an association between 
the minimum ADC (ADCmin), determined on DW-
MRI, and Ki-67, which is a cellular proliferative 
index. Our secondary aim was to assess whether 
ADCmin values differ between the adenocarcino-
mas and squamous cell carcinomas of the lungs 
and also differ according to the pathologic sam-




Between January 2012 and December 2013, records 
for 104 consecutive patients with histopathologi-
cally proven primary adenocarcinoma and squa-
mous cell carcinoma of the lungs, and who had 
technically successful images on DW-MRI were 
retrieved from the hospital’s pathology database. 
The patients who were previously treated (n = 5) 
and\or had an interval of more than 15 days be-
tween DW-MRI and biopsy (n = 6) were excluded 
from the study. All measurements, including cal-
culation of Ki-67 index and ADCmin values, were 
done in the same lesion for each patient. The proto-
col of the retrospective study was approved by the 
institutional ethics committee and the requirement 
for informed consent was waived.
Imaging technique, DW-MRI
It was performed with a 3 tesla scanner 
(MAGNETOM Skyra, Siemens Healthcare, 
Erlangen, Germany). Conventional MRI included 
an axial T1-weighted sequence (repetition time, 
104 ms; echo time, 4.92 ms; 1 excitation) and an 
axial T2-weighted sequence (repetition time, 1400 
ms; echo time, 101 ms; 1 excitation). Breath-free 
DW-MRI was performed in the axial plane using 
a single-shot, spin-echo echo-planar imaging se-
quence with the following parameters: repetition 
time, 6500 ms; echo time, 61 ms; real spatial resolu-
tion in the phase-encoding direction, 3.7 mm; flip 
angle, 900; diffusion gradient encoding in three or-
thogonal directions; b value b = 50, b = 400 and b = 
800 s/mm2; field of view, 380 mm x 380 mm x 310 
mm; matrix size, 113 x 192; slice thickness, 6 mm; 
section gap, 0 mm; 2 signals acquired. 
Image analysis
We analysed the lesions using DW-MRI images in 
association with T1- and T2-weighted images in or-
der to identify accurately. The ADC of the tumour 
was then calculated to quantitatively analyse the 
degree of diffusion, using the following formula: 
ADC = −ln(S/S0) / (b−b0), where S0 and S are the 
signal intensities, obtained at three different diffu-
sion gradients (b = 50, b = 400 and b = 800 s/mm2). 
The ADC maps were reconstructed at a worksta-
tion. While establishing the size and region for the 
ROI, positioning in the larger area was considered 
in order to minimize the effect of region on hemo-
dynamic inhomogeneity of tumour by avoiding 
necrotic, cystic or calcific areas by referring to T2 
and T1-weighted images.28,29 The ADCmin values 
within the ROI were then used in statistical analy-
ses (Figure 1). In analyses workstation (Syngo Via 
Console, software version 2.0, Siemens AG Medical 
Solutions, Erlangen, Germany) was used.
Calculation of Ki-67 index
Archived paraffin blocks belonging to the patients 
were transferred to polylysine glass slides with 
4-micron thick sections. Immunochemistry was 
performed using a Lecia Bond-max automated 
immunostainer (Leica Microsystems, Newcastle, 
UK), as described manufacturers protocol. For Ki-
67 staining, Ki-67 antibody (NCL-L-Ki67-MM1, 
monoclonal, 1:60, Novocostra, Newcastle, UK) was 
used. The sections prepared for examination were 
evaluated by two pathologists who were blinded 
to each-other. Firstly, ten areas having highest ex-
pression of Ki-67 were determined at low magnifi-
cation. Then, these areas were further analysed at 
a single high power field (400 x magnification). Ki-
67 expression was defined as the percent of Ki-67-
positive tumour cells divided by the total number 
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of tumour cell within one high power field.26,30 In 
the last step, Ki-67 index was calculated as the av-
erage percentage of those fields.
FIGURE 1. Diffusion-weighted (DW)-MRI, apparent diffusion coefficient (ADC) 
map of a 62-year-old female with adenocarcinoma. (A) Tumour shows 
heterogeneously high signal intensity on DW-MRI, for which the b value is 800 s/
mm2. (B) On the ADC map, the tumour demonstrates heterogeneous diffusion 
restriction. (C) Proli ferative index 95% in glandular epithelium (Ki-67X400).
Statistical Analysis
Analyses were performed using IBM SPSS 20.0 for 
Mac software. The correlation between ADCmin and 
the Ki-67 index was evaluated using Spearman’s 
correlation coefficient. Mann-Whitney U tests were 
used to assess the difference between the ADCmin 
and the Ki-67 index for the different tumour sub-
types. A p value of less than 0.05 was considered 
statistically significant.
Results
Ninety three patients, with a mean age 65 ± 11 
years ranged between 43 and 84, with histopatho-
logically proven primary adenocarcinoma (n = 47) 
and squamous cell carcinoma (n = 46) of the lungs 
and had technically successful DW-MRI were in-
cluded in the study. Histopathological diagnoses 
were obtained through transthoracic or transbron-
chial biopsy in 65 subjects and 28 patients under-
went surgery. 
The mean ADCmin value for all the lesions was 
0.77 ± 0.15 x 10-3 mm2/sec (range, 0.50–1.00 x 10-3 
mm2/sec). The mean ADCmin value for adenocarci-
nomas was 0.83 ± 0.12 x 10-3 mm2/sec and that of 
squamous cell carcinomas was 0.70 ± 0.16 x 10-3 
mm2/sec; there was a significant difference be-
tween these values (p < 0.0001). The mean Ki-67 
was 43.5 ± 22.2 for all the tumours (range, 5–96), 
with a mean of 30.8 ± 14.1 for adenocarcinomas and 
55.9 ± 21.8 for squamous cell carcinoma; the differ-
ence between tumour subtypes was significant (p 
< 0.0001). 
There was a negative correlation between 
ADCmin values and the Ki-67 proliferation index 
(p < 0.001, r = -0.837) (Figure 2). The ADCmin values 
were lower in the cases with higher Ki-67 grades. 
The mean ADCmin values and Ki-67 index for ade-
nocarcinomas and squamous cell carcinomas of the 
lung are shown in Figure 3. There was no statistical 
difference of Ki-67 and ADCmin values between bi-
opsied material and surgical specimen. The mean 
Ki-67 was 45.3 ± 22.8 vs 39.3 ± 19.8 and the mean 
ADCmin value was 0.76 ± 0.16x10-3 vs 0.78 ± 0.14 x 10-3 
for biopsied material and surgical specimen, re-
spectively. In the comparative evaluation of corre-
lation between ADCmin and the Ki-67 proliferation 
index that measured either in surgical specimen or 
biopsied material, the Ki-67 index of surgical speci-
mens was slightly better correlated with ADCmin 
values without statistical significance (r = -0.870 vs. 
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Discussion
Our results showed that there is a negative cor-
relation between the ADCmin and the Ki-67 index 
of lung cancers, which reflects aggressiveness of 
a tumour. ADCmin values for adenocarcinomas 
were higher than those for squamous cell carcino-
mas. This finding indicates that ADCmin may have 
a role in discriminating adenocarcinomas from 
squamous cell carcinomas, as well as being used 
for evaluating the aggressiveness of the tumour. 
Also, a low ADCmin value can potentially be used 
as a non-invasive surrogate biomarker for the Ki-67 
index for the evaluation of lung tumour character-
istics, regardless of subtype.
Lung cancer is the leading cause of cancer-re-
lated deaths.31 Until now, the Ki-67 proliferation 
index, reflecting aggressiveness of a tumour has 
been used to determine the prognosis. Malignant 
tumours are characterized by increased Ki-67 pro-
liferation index due to their cellularity, larger nu-
clei with more abundant macromolecular proteins, 
a larger nuclear/cytoplasmic ratio and less extracel-
lular space relative to normal tissue. As these char-
acteristics also restrict the diffusion of water mole-
cules, ADCmin decreases in malignant tumours.8,9,32 
Because ADCmin is found to have stronger cor-
relation with Ki-67 index compared to ADCmean, we 
used ADCmin in our study.15 Apparent diffusion co-
efficient can be used in the non-invasive assessment 
of suspicious masses, for example, to differentiate 
metastatic lymph nodes from those that are benign 
when they cannot be differentiated by size criteria.5 
ADC values also correlate with tumour grades.4,17,18 
Recent studies have shown that ADC may be more 
useful than FDG-PET in the differentiation of ma-
lignant tumours from benign lesions3,6 and the new 
approaches using PET\MRI may provide more 
promising results in the future.33 Among primary 
lung cancers, ADC values are usually low in cases 
with small cell carcinomas, but the values for ad-
enocarcinomas and squamous cell carcinomas are 
usually similar.3,4 However Matoba et al. stated 
that ADCs of well-differentiated adenocarcinoma 
appear to be higher than those of other histologic 
lung carcinoma types.23 Our findings demonstrate 
that adenocarcinomas showed higher ADC values 
than squamous cell carcinomas, and had weaker 
staining diffusivity and intensity of Ki-67.
A high Ki-67 and low ADCmin value indicates 
that a tumour has a high proliferation rate. Ki-67 
values obtained using an invasive method reflect 
only the level in the sampled tissue; this is a particu-
lar problem when using biopsy. Since lung carci-
nomas are not always homogenous, the biopsy site 
can influence the results. This could be reflected in 
the fact that in our study the correlation between 
ADCmin and Ki-67 proliferation index was stronger 
for surgical than for biopsy samples. Unlike these 
invasive sampling methods, ADCmin values ob-
tained by DW-MRI in a non-invasive manner can be 
calculated from anywhere in the tumour, provid-
ing an entire and reproducible assessment of the tu-
mour. Furthermore, since the region with the low-
est ADCmin value is likely to be the most aggressive 
portion.17,34 DWI could also help in the selection of 
an appropriate biopsy site within the tumour.
FIGURE 2. The graph shows a negative correlation between the 
minimum apparent diffusion coefficient (ADCmin) and the Ki-67 
index in lung tumours (r = -0.837, p < 0.001).
FIGURE 3. The graph shows average minimum apparent 
diffusion coefficient (ADCmin) values for adenocarcinoma and 
squamous cell carcinoma according to Ki-67 index. Bars are for 
ADCmin values and line is for Ki-67. 
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An association between the ADC value and the 
Ki-67 index has been shown for various kinds of tu-
mours2,14-18,34-38, including lung cancer.3,6 Wang et al., 
in their study on DWI in pancreatic endocrine tu-
mours, reported a correlation coefficient of -0.702, 
while Onishi et al. reported a correlation coefficient 
of -0.825 for mucinous breast carcinoma.15
Previous studies reporting ADC values of lung 
carcinoma have been conducted under various 
magnet strengths, and reported ADC values are 
lower in magnets with a stronger field. Matoba et 
al. reported mean ADC values of 1.63 × 10−3 mm2/
sec ± 0.5 (mean ± SD) for squamous cell carcinomas, 
2.12 × 10−3 mm2/sec ± 0.6 for adenocarcinomas, 1.30 
× 10−3 mm2/sec ± 0.4 for large-cell carcinomas, and 
2.09 × 10−3 mm2/sec ± 0.3 for small-cell carcinomas, 
using a 1.5 T scanner. Usuda et al.6 found that ma-
lignant nodules had a mean ADC of 1.27 ± 0.35 ×10-
3 mm2/sec on a 1.5T system. Using a 3.0 T scanner, 
Zhang et al. reported that malignant pulmonary 
nodules had a mean ADC of 0.87 ± 0.16 × 10−3 mm2/
sec. Similarly, we found a mean ADCmin of 0.77 ± 
0.12 x 10-3 mm2/sec in our study conducted on a 3.0 
T scanner. These values are lower than those were 
reported by the studies conducted using 1.5 T sys-
tems.6,23 However, Kivrak et al. noted that ADC val-
ues vary for different MRI systems with the same 
magnetic field strength (1.5 T).39 On the other hand, 
some authors reported that ADC values might not 
change for different organ systems under different 
magnetic fields.40 However, they only used healthy 
volunteers and neither pathologic conditions nor 
image quality was not assessed. Further work is 
still needed to investigate the effect of magnetic 
field strength on the ADC of different organ sys-
tems. 
One of the strongest side of our study was that 
we used 3 tesla MRI, which has increased signal to 
noise ratio, spatial resolution, temporal resolution, 
etc. Thus, decreased imaging time increased pa-
tients’ cooperation and we had better qualified im-
ages. Our study had a few limitations. Our study 
population was relatively small and, although 
our results are robust, prospective studies with 
larger series are warranted to confirm our results. 
Additionally, to be able to generalize our results to 
all subtypes of lung cancer, such as small cell car-
cinomas and the other subtypes of non-small cell 
lung cancer, which we had very limited number of 
such cases during the study period, need to be in-
cluded in future studies. Because we had no data 
about survival of the cases, we could not conclude 
any association between ADCmin or Ki-67 and sur-
vival. However, use of ADCmin may provide new 
insight to the evaluation of lung cancer including 
benign-malignant discrimination, the possibility 
of evaluation all lesions and lymph nodes non-
invasively, even in the cases that tissue sampling 
is difficult, as well as predicting the prognosis of 
tumour by using it as a surrogate marker of Ki-67 
index.
In conclusion, our results suggested that ADCmin 
values were inversely correlated with Ki-67 index 
in non-small cell lung cancer and may be used as a 
surrogate marker of Ki-67 index in the evaluation 
of tumour aggressiveness with the advantage of its 
non-invasiveness and without requirement of tis-
sue sampling of all the lesions.
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